Trial Profile
A Phase 1b, Open-Label, Parallel Single-Dose Study to Evaluate the Pharmacokinetics and Pharmacodynamics of Tinlarebant in Healthy Volunteers Aged 50-85
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 28 Feb 2023
Price :
$35
*
At a glance
- Drugs Tinlarebant (Primary)
- Indications Dry age-related macular degeneration; Stargardt disease
- Focus Pharmacodynamics; Pharmacokinetics
- 21 Feb 2023 Status changed from not yet recruiting to completed.